Page 20 - Read Online
P. 20

Naeem et al. Hepatoma Res 2018;4:18  I  http://dx.doi.org/10.20517/2394-5079.2018.22                                         Page 3 of 10


                                                       Hepatocelluar
                                                        carcinoma



                                   Curative                                   Palliative



                     Resection     Ablation     Transplant      Chemo-        Sorafenib    Supportive
                       PST 0        PST 0         PST 0       emblization
                     Single lesion                               1-3   1-3 nodules   PST 1-2  PST > 2
                      < 2 cm;       nodules      < 3 cm;         PST 0
                      Stage  0      < 3 cm;     Stage 0-A                      Stage C       Stage D
                     Normal portal   Stage 0-A   Normal/       Multinodular   (advanced)    (terminal)
                      pressure      Normal/      inc Portal      lesion
                     and bilirubin   inc Portal   pressure                   Portal invasion  Child-Pugh C
                       levels;      pressure     and/or         Stage B
                      Child-Pugh    and/or       bilirubin;   (intermediate)
                        A;         bilirubin;   Child-Pugh
                     No associated   Child-Pugh   A-B;         Child-Pugh
                       disease       A-B       No associated      A-B
                                                 disease


                       Figure 1. Treatment algorithm based on disease and patient characteristics, adapted from the BCLC staging system


               being replaced by newer modalities like Radiofrequency ablation. Although encouraging results have been
               reported for both in terms of treatment response and long-term survival, differences exist in terms of
               applicability and adverse effects of each, and the decision to use one over the other is often individualized to
               each patient and requires careful patient evaluation and triage.



               PERCUTANEOUS ETHANOL INJECTION
               Percutaneous ethanol injection (PEI), performed under local anaesthesia with ultrasound guidance, involves
               injecting ethanol intra-lesionally using non-cutting needles over multiple sessions in the outpatient setting.
               By promoting cellular dehydration and occlusion of smaller tumor vessels, ethanol induces coagulative
               necrosis and a fibrous reaction leading to complete necrosis of most lesions. PEI is a well-established therapy,
               particularly for the treatment of nodular HCC, owing to the ability of ethanol to diffuse through the soft
               malignant tissue and the firm consistency of the surrounding cirrhotic liver parenchyma .
                                                                                          [13]
               In general, tumour response following PEI is determined by the size of the lesion as well the degree of
               hepatic dysfunction. Tumours smaller than 2 cm show the best response in terms of disease eradication
               with 90%-100% of lesions showing complete response, while larger lesions have shown a high rate of local
               recurrence when treated with PEI [14-16] . This is postulated to be due to septae within larger lesions, presenting
               barriers to the diffusion of ethanol, leading to an incomplete response. With recent technological advances
               however, including the introduction of a multipronged needle with retractable prongs, even larger tumors
               up to 4 cm in size have demonstrated complete response rates as high as 80%-90% .
                                                                                    [17]

               With 5-year survival rates as high as 47%-53% in patients with early stage disease, PEI has shown encouraging
               results [18,19] . It is however, associated with a high local recurrence rate of 43%, particularly for lesions larger
               than 3 cm in diameter, which undermines its curative capacity when compared with newer ablative modalities
               like radiofrequency ablation (RFA) .
                                             [20]
   15   16   17   18   19   20   21   22   23   24   25